The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack

INTRODUCTION: Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA). Conversion of clopidogrel to its active metabolite by hepatic cytochrome P450-2C19 (CYP2C19) is essential for the inhibition of the P2Y12 receptor and...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, John H, Leach, Marc, Sen, Dwaipayan, Smith, Craig J., Newman, William G., Bath, Philip M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612933/
https://www.ncbi.nlm.nih.gov/pubmed/35912831
http://dx.doi.org/10.1080/17512433.2022.2108401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612933/
https://www.ncbi.nlm.nih.gov/pubmed/35912831
http://dx.doi.org/10.1080/17512433.2022.2108401

Ejemplares similares